This is a severe form of nearsightedness that can cause serious eye problems. It often develops later in life and can lead to blindness if not treated. It involves changes in the eye's shape and can cause blood vessels to grow abnormally in the back of the eye.
Every report comes from a Lived member, sent anonymously.
Have you tried Lucentis (Ranibizumab) for Degenerative Myopia?
Degenerative myopia, also called pathologic myopia, is a form of nearsightedness in which the eyeball has stretched so far that the tissues lining the back of the eye begin to thin and break down. That damage, rather than blurry distance vision, is what makes the condition serious: it can cause vision loss that glasses or contact lenses cannot correct. It is not the same as simply having a strong prescription. Many people with high myopia (a nearsighted prescription of about -5.00 diopters or stronger, where the minus sign marks nearsightedness and the number its strength) have healthy retinas. Degenerative myopia is diagnosed when characteristic changes appear at the back of the eye, such as a posterior staphyloma (an outward bulge in the stretched eye wall) or thinning and scarring of the macula, the small central part of the retina that provides sharp vision for reading and recognizing faces. It is a leading cause of permanent vision loss in parts of East Asia and an important cause of low vision in working-age and older adults worldwide.
The underlying problem is excessive lengthening of the eye from front to back. As the eye grows longer, the retina, the choroid (the blood vessel layer that nourishes it) and the eye's tough outer wall are all stretched thin, and that stretching produces the damage that defines the condition. The degree of nearsightedness is the clearest risk factor. Most people with degenerative myopia are highly nearsighted, and the chance of these changes rises steeply with each step up in prescription and eye length. It is not strictly limited to strong prescriptions, though: a staphyloma can occasionally form in an eye of ordinary length. Once changes have begun, older age, a longer eye and the presence of a staphyloma are the main factors linked to further progression. Nearsightedness often runs in families, but the genetics of the degenerative form are not well understood. For common childhood nearsightedness, intensive near work and little time outdoors are associated with higher risk. Whether changing those habits prevents degenerative damage later in life has not been shown.
Diagnosis rests on a dilated eye exam by an ophthalmologist or optometrist, who examines the retina and optic nerve for the typical changes. Alongside the prescription, many clinics measure axial length, the front-to-back length of the eye in millimeters. Complications become much more common as length increases: in one large study, diffuse thinning of the retina's supporting layers was found in under 4% of eyes shorter than 26.5 mm but in more than 60% of eyes 28.5 mm or longer. Optical coherence tomography (OCT), a quick, painless scan that produces cross-section images of the retina, is central to the assessment. It shows thinning of the choroid, stretching or splitting of the retinal layers, and fluid or abnormal vessels under the macula. If new blood vessels are suspected, they are confirmed with an angiogram, in which dye injected into an arm vein is photographed as it passes through the eye, or with OCT angiography, a scan that needs no dye. Eye doctors often grade the damage in stages. The earliest, a tessellated or striped-looking retina where the underlying vessels show through, does not usually affect vision and on its own is not counted as degenerative myopia. Later stages are diffuse thinning, patchy areas of tissue loss (atrophy) and finally atrophy of the macula itself. Lacquer cracks (fine breaks in the layers beneath the retina) and abnormal new vessels are recorded separately, because they can threaten central vision at any stage.
No current treatment reverses the stretching of the eye or restores tissue that has already thinned. Care focuses on correcting focus, catching complications early and treating the ones that can be treated. Glasses or contact lenses still correct the blur of nearsightedness, but they cannot fix vision lost to retinal damage. The most important treatable complication is myopic choroidal neovascularization (CNV): fragile new blood vessels that grow under the macula and leak or bleed. Without treatment, it usually leads to severe, lasting loss of central vision within a few years. It is treated with medicines that block vascular endothelial growth factor (VEGF), a signal these vessels need to grow, and are therefore called anti-VEGF drugs. Ranibizumab (Lucentis) is approved by the US Food and Drug Administration (FDA) for this use, and eye doctors also use related drugs such as aflibercept (Eylea), which is approved for other retinal diseases but not specifically for this one. The medicine is injected into the eye in the office after numbing drops. In clinical trials, people typically gained two to three lines on the eye chart within a year, after about three to five injections. Follow-up scans continue afterward because the vessels become active again in a substantial share of eyes, and over the long term, thinning around the treated area can slowly wear away some of the vision gained. When the stretching pulls the retinal layers apart (myopic traction maculopathy, sometimes called foveoschisis), a retina surgeon may recommend a vitrectomy, an operation that removes the gel inside the eye to relieve the pull. Surgery is generally reserved for eyes whose vision is declining or that develop a detachment at the center, because operating on a stable eye without symptoms can make vision worse, and results are less good once a hole has formed in the macula. A retinal detachment elsewhere in the eye is also repaired surgically. Very long eyes are more prone to glaucoma-like damage to the optic nerve, so the nerve is checked as part of ongoing care. When central vision is permanently reduced, low vision rehabilitation can teach the use of magnifiers, screen readers, brighter task lighting and other aids that make reading and daily tasks easier.
Degenerative myopia is lifelong and usually changes slowly, over years to decades rather than weeks. Many people keep useful vision for a long time, particularly while damage stays away from the very center of the macula. The course is uneven, though. Changes tend to progress faster once the earliest stage has passed, and a complication such as CNV can cause a sudden drop in vision in one eye. The effect on daily life depends on where the damage sits. Patchy atrophy usually creates blind spots beside the center of vision rather than at it, which can make reading, recognizing faces or following a line of text harder before the eye chart shows much change. Atrophy of the macula itself, or scarring after CNV, affects central vision directly. In those situations, magnification, good lighting, high-contrast settings on devices and vision rehabilitation can help people keep reading, working and managing at home. Regular dilated exams and OCT scans, on a schedule your eye doctor sets according to your findings, are how treatable problems are caught early. Extreme nearsightedness raises the risk of retinal detachment, and so does cataract surgery, so the warning signs below are worth knowing well, especially after any eye operation.
Arrange an exam with an eye doctor if you are highly nearsighted and have not had a dilated exam recently, or if your vision has gradually worsened even with an updated prescription. Contact your eye doctor promptly, without waiting for a routine visit, if you notice new distortion (straight lines looking wavy or bent), new blurring in the center of your vision or a new dark or blank spot. These can signal abnormal blood vessels under the macula, and treatment tends to work better when it starts soon after symptoms begin. A sudden shower of new floaters, flashes of light, or a shadow or curtain spreading across part of your vision can mean a retinal detachment, which is an emergency: see an eye care professional immediately. If you are having eye injections and the treated eye becomes red, painful or sensitive to light, or your vision worsens in the days afterward, seek immediate care from your ophthalmologist, since these can be signs of infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Degenerative Myopia is like, what's helped you, or ask the community a question.